Lunit Secures Landmark Deal to Provide Breast AI Technology to French Public Hospitals
Lunit, a renowned innovator in AI solutions for cancer diagnostics and therapeutics, has made a groundbreaking advancement by securing a national framework agreement with UniHA, the leading public procurement organization for French hospitals. This historic deal enables Lunit's breast imaging AI technologies, namely Lunit INSIGHT® MMG and DBT, to be available to over 1,500 public hospitals across France, thanks to the collaboration with Fujifilm, a primary contractor on this project.
This four-year contract eliminates the need for separate tender processes for each hospital, thereby facilitating a streamlined adoption of innovative breast AI solutions nationwide. The significance of winning this tender cannot be overstated—it marks a pivotal breakthrough for Lunit in a market traditionally dominated by local vendors.
Brandon Suh, CEO of Lunit, expressed enthusiasm about this new opportunity, stating, "This national framework agreement represents a unique chance for us to expand our AI solutions across public hospitals in France, a market of immense strategic importance in Europe. Winning this competitive contract, particularly with our long-standing partner Fujifilm, not only showcases our strength in breast cancer screening technologies but also reinforces our credibility within the public healthcare sector."
Bertrand Lepage, who manages the Biomedical Engineering Program at UniHA, highlighted the growing demand for AI in mammography, noting, "Our recent call for tenders aimed to ensure that public hospitals have access to the most effective technologies available, under equitable conditions to those in the private sector."
The significance of Lunit's technology, especially in the context of breast health, is underscored by Dr. Eric Kamus, a radiologist at Lille University Hospital, which is part of the UniHA network. Dr. Kamus shared his positive experience using Lunit's AI solution in conjunction with Fujifilm’s Amulet mammography device, stating, “As someone who has practiced breast imaging since the 1980s, I rely on Lunit as a critical safety net that enhances my focus and accuracy. The technology is particularly comforting for patients, knowing that an AI system is also analyzing their images, especially in such a sensitive area as breast cancer diagnostics.”
Founded in 2013, Lunit aims to conquer cancer through the development of AI-powered healthcare solutions. The company's Lunit INSIGHT suite of tools is FDA-cleared and supports cancer screening at over 7,000 medical institutions spread across more than 65 countries worldwide. Lunit maintains a strong research presence, with clinical studies featured in high-profile journals, such as The Lancet Digital Health and Journal of Clinical Oncology, and presented at major conferences like ASCO and RSNA. Headquartered in Seoul, with offices around the globe, Lunit continues its mission to advance cancer detection and treatment through the innovative application of artificial intelligence. Learn more about how Lunit is revolutionizing cancer care by visiting lunit.io.
This four-year contract eliminates the need for separate tender processes for each hospital, thereby facilitating a streamlined adoption of innovative breast AI solutions nationwide. The significance of winning this tender cannot be overstated—it marks a pivotal breakthrough for Lunit in a market traditionally dominated by local vendors.
Brandon Suh, CEO of Lunit, expressed enthusiasm about this new opportunity, stating, "This national framework agreement represents a unique chance for us to expand our AI solutions across public hospitals in France, a market of immense strategic importance in Europe. Winning this competitive contract, particularly with our long-standing partner Fujifilm, not only showcases our strength in breast cancer screening technologies but also reinforces our credibility within the public healthcare sector."
Bertrand Lepage, who manages the Biomedical Engineering Program at UniHA, highlighted the growing demand for AI in mammography, noting, "Our recent call for tenders aimed to ensure that public hospitals have access to the most effective technologies available, under equitable conditions to those in the private sector."
The significance of Lunit's technology, especially in the context of breast health, is underscored by Dr. Eric Kamus, a radiologist at Lille University Hospital, which is part of the UniHA network. Dr. Kamus shared his positive experience using Lunit's AI solution in conjunction with Fujifilm’s Amulet mammography device, stating, “As someone who has practiced breast imaging since the 1980s, I rely on Lunit as a critical safety net that enhances my focus and accuracy. The technology is particularly comforting for patients, knowing that an AI system is also analyzing their images, especially in such a sensitive area as breast cancer diagnostics.”
Founded in 2013, Lunit aims to conquer cancer through the development of AI-powered healthcare solutions. The company's Lunit INSIGHT suite of tools is FDA-cleared and supports cancer screening at over 7,000 medical institutions spread across more than 65 countries worldwide. Lunit maintains a strong research presence, with clinical studies featured in high-profile journals, such as The Lancet Digital Health and Journal of Clinical Oncology, and presented at major conferences like ASCO and RSNA. Headquartered in Seoul, with offices around the globe, Lunit continues its mission to advance cancer detection and treatment through the innovative application of artificial intelligence. Learn more about how Lunit is revolutionizing cancer care by visiting lunit.io.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.